Advances in Therapy

, Volume 31, Issue 9, pp 945–960

Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

  • Alfonso Berrocal
  • Luis Cabañas
  • Enrique Espinosa
  • Ricardo Fernández-de-Misa
  • Salvador Martín-Algarra
  • José Carlos Martínez-Cedres
  • Luis Ríos-Buceta
  • José Luis Rodríguez-Peralto


The incidence of malignant melanoma is increasing worldwide. In Spain, its incidence is increasing faster than any other cancer type, with a 5-year survival rate of about 85%. The impact and characteristics of malignant melanoma in the Spanish population can be ascertained from the national melanoma registry of the Academia Española de Dermatología y Venereología. This review presents consensus group recommendations for the diagnosis, staging and treatment of malignant melanoma in Spain. Incidence and mortality are discussed, as well as evaluation of various prevention and treatment strategies. Prognostic factors, such as BRAF and C-KIT mutations, which are expected to become routine staging procedures over the next few years, are outlined, especially in relation to treatment options. The use of recently approved targeted agents such as ipilimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitor, and vemurafenib, a BRAF inhibitor, in metastatic disease are also discussed.


Diagnosis Malignant melanoma Oncology Prognosis Spain Standards Therapeutics 

Supplementary material

12325_2014_148_MOESM1_ESM.pdf (267 kb)
Supplementary material 1 (PDF 266 kb)


  1. 1.
    Marcos-Gragera R, Vilar-Coromina N, Galceran J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.PubMedGoogle Scholar
  2. 2.
    Saenz S, Conejo-Mir J, Cayuela A. Melanoma epidemiology in Spain. Actas Dermosifiliogr. 2005;96(7):411–8.PubMedGoogle Scholar
  3. 3.
    Cabanes A, Vidal E, Aragones N, et al. Cancer mortality trends in Spain: 1980–2007. Ann Oncol. 2010;21 Suppl 3:iii14–20.Google Scholar
  4. 4.
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedGoogle Scholar
  5. 5.
    Chirlaque MD, Salmeron D, Ardanaz E, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010:21 Suppl 3:iii21–29.Google Scholar
  6. 6.
    Newton-Bishop JA, Chang YM, Elliott F, et al. Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case–control study in a temperate climate. Eur J Cancer. 2011;47(5):732–41.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Newton-Bishop JA, Chang YM, Iles MM, et al. Melanocytic nevi, nevus genes, and melanoma risk in a large case–control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2043–54.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1241–4.PubMedGoogle Scholar
  9. 9.
    Marghoob AA, Schoenbach SP, Kopf AW, et al. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol. 1996;132(2):170–5.PubMedGoogle Scholar
  10. 10.
    Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised UK guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163(2):238–56.PubMedGoogle Scholar
  11. 11.
    Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med. 2003;349(23):2233–40.PubMedGoogle Scholar
  12. 12.
    Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol. 2005;23(13):3043–51.PubMedGoogle Scholar
  13. 13.
    Chen GJ, Feldman SR, Williford PM, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg. 2005;31(1):43–7.PubMedGoogle Scholar
  14. 14.
    Troyanova P, Danon S, Ivanova T. Nonmelanoma skin cancers and risk of subsequent malignancies: a cancer registry-based study in Bulgaria. Neoplasma. 2002;49(2):81–5.PubMedGoogle Scholar
  15. 15.
    Hollenbeak CS, Todd MM, Billingsley EM, et al. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104(9):1962–7.PubMedGoogle Scholar
  16. 16.
    Montella M, Crispo A, Grimaldi M, et al. An assessment of factors related to tumor thickness and delay in diagnosis of melanoma in southern Italy. Prev Med. 2002;35(3):271–7.PubMedGoogle Scholar
  17. 17.
    Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63.PubMedGoogle Scholar
  18. 18.
    Durbec F, Vitry F, Granel-Brocard F, et al. The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France. Arch Dermatol. 2010;146(3):240–6.PubMedGoogle Scholar
  19. 19.
    Brady MS, Oliveria SA, Christos PJ, et al. Patterns of detection in patients with cutaneous melanoma. Cancer. 2000;89(2):342–7.PubMedGoogle Scholar
  20. 20.
    Andersen WK, Silvers DN. ‘Melanoma? It can’t be melanoma!’ A subset of melanomas that defies clinical recognition. JAMA. 1991;266(24):3463–5.PubMedGoogle Scholar
  21. 21.
    McPherson M, Elwood M, English DR, et al. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol. 2006;54(5):783–92.PubMedGoogle Scholar
  22. 22.
    Schwartz JL, Wang TS, Hamilton TA, et al. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer. 2002;95(7):1562–8.PubMedGoogle Scholar
  23. 23.
    Tran KT, Wright NA, Cockerell CJ. Biopsy of the pigmented lesion—when and how. J Am Acad Dermatol. 2008;59(5):852–71.PubMedGoogle Scholar
  24. 24.
    Nagore E, Botella-Estrada R, Requena C, et al. Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site. Actas Dermosifiliogr. 2009;100(3):205–11.PubMedGoogle Scholar
  25. 25.
    Dolianitis C, Kelly J, Wolfe R, et al. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. Arch Dermatol. 2005;141(8):1008–14.PubMedGoogle Scholar
  26. 26.
    Carli P, Quercioli E, Sestini S, et al. Pattern analysis, not simplified algorithms, is the most reliable method for teaching dermoscopy for melanoma diagnosis to residents in dermatology. Br J Dermatol. 2003;148(5):981–4.PubMedGoogle Scholar
  27. 27.
    Nachbar F, Stolz W, Merkle T, et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. J Am Acad Dermatol. 1994;30(4):551–9.PubMedGoogle Scholar
  28. 28.
    Pagnanelli G, Soyer HP, Argenziano G, et al. Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts. Br J Dermatol. 2003;148(4):698–702.PubMedGoogle Scholar
  29. 29.
    Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol. 2003;48(5):679–93.PubMedGoogle Scholar
  30. 30.
    Blum A, Rassner G, Garbe C. Modified ABC-point list of dermoscopy: a simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. J Am Acad Dermatol. 2003;48(5):672–8.PubMedGoogle Scholar
  31. 31.
    Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol. 2007;56(5):759–67.PubMedGoogle Scholar
  32. 32.
    Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771–6.PubMedGoogle Scholar
  33. 33.
    Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142(12):1551–8.PubMedGoogle Scholar
  34. 34.
    Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol. 1987;17(4):571–83.PubMedGoogle Scholar
  35. 35.
    Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159–65.PubMedGoogle Scholar
  36. 36.
    Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001;45(4):579–86.PubMedGoogle Scholar
  37. 37.
    Koller J, Rettenbacher L. The influence of diagnostic biopsies on the sentinel lymph node detection in cutaneous melanoma. Arch Dermatol. 2000;136(9):1176.PubMedGoogle Scholar
  38. 38.
    Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Canc Netw. 2009;7(3):250–75.PubMedGoogle Scholar
  39. 39.
    Cockerell CJ. Biopsy technique for pigmented lesions. Semin Cutan Med Surg. 1997;16(2):108–12.PubMedGoogle Scholar
  40. 40.
    Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Modern Pathol. 2006;19(Suppl):S34–40.Google Scholar
  41. 41.
    Hantschke M, Bastian BC, LeBoit PE. Consumption of the epidermis: a diagnostic criterion for the differential diagnosis of melanoma and Spitz nevus. Am J Surg Pathol. 2004;28(12):1621–5.PubMedGoogle Scholar
  42. 42.
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902–8.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48.PubMedGoogle Scholar
  44. 44.
    Weedon D. Skin pathology. 2nd ed. Edinburgh: Churchill Livingstone; 2002.Google Scholar
  45. 45.
    Clark JW. A classification of malignant melanoma in man correlated with histogenesis and biologic behaviour. In: Montagna W, Hu F (eds) Advances in the biology of the skin, vol 8. New York: Pergamon; 1967.Google Scholar
  46. 46.
    Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705–27.PubMedGoogle Scholar
  47. 47.
    Schmid-Wendtner MH, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res. 2001;11(6):619–26.PubMedGoogle Scholar
  48. 48.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Arrington JH 3rd, Reed RJ, Ichinose H, et al. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol. 1977;1(2):131–43.PubMedGoogle Scholar
  50. 50.
    Ferringer T. Update on immunohistochemistry in melanocytic lesions. Dermatol Clin. 2012;30(4):567–79.PubMedGoogle Scholar
  51. 51.
    Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164(1):193–203.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Schramm SJ, Mann GJ. Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther. 2011;10(8):1520–8.PubMedGoogle Scholar
  53. 53.
    Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res. 2007;17(6):393–9.PubMedGoogle Scholar
  54. 54.
    Houghton AN, Coit DG, Daud A, et al. Melanoma. J Natl Compr Canc Netw. 2006;4(7):666–84.PubMedGoogle Scholar
  55. 55.
    Saiag P, Bosquet L, Guillot B, et al. Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, options and recommendations guidelines. Summary report. Eur J Dermatol. 2007;17(4):325–31.PubMedGoogle Scholar
  56. 56.
    Stoffels I, Dissemond J, Poeppel T, et al. Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC Stages I and II. J Eur Acad Dermatol Venereol. 2012;26(1):79–85.PubMedGoogle Scholar
  57. 57.
    Patnana M, Bronstein Y, Szklaruk J, et al. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol. 2011;66(3):224–36.PubMedGoogle Scholar
  58. 58.
    Hausmann D, Jochum S, Utikal J, et al. Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma. J Dtsch Dermatol Ges. 2011;9(3):212–22.PubMedGoogle Scholar
  59. 59.
    Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27(28):4774–80.PubMedGoogle Scholar
  60. 60.
    Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol. 2001;8(2):101–8.PubMedGoogle Scholar
  61. 61.
    Agarwala S, Lee S, Flaherty L, et al. Randomized phase III trial of high-dose interferon alfa-2b for 4 weeks induction only in patients with intermediate- and high-risk melanoma. J Clin Oncol. 2011;29: abstr 8505.Google Scholar
  62. 62.
    Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358(9285):866–9.PubMedGoogle Scholar
  63. 63.
    Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13(11):2776–83.PubMedGoogle Scholar
  64. 64.
    Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189–96.PubMedGoogle Scholar
  65. 65.
    Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–26.PubMedGoogle Scholar
  66. 66.
    Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905–10.PubMedGoogle Scholar
  67. 67.
    Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53–61.PubMedGoogle Scholar
  68. 68.
    Hansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011;12(2):144–52.PubMedGoogle Scholar
  69. 69.
    Hauschild A, Weichenthal M, Rass K, et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol. 2009;27(21):3496–502.PubMedGoogle Scholar
  70. 70.
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.PubMedGoogle Scholar
  71. 71.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.PubMedGoogle Scholar
  72. 72.
    Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.PubMedGoogle Scholar
  73. 73.
    Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16(4):1425–9.PubMedGoogle Scholar
  74. 74.
    Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon alpha-2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195–201.PubMedGoogle Scholar
  75. 75.
    Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.PubMedGoogle Scholar
  76. 76.
    Pirard D, Heenen M, Melot C, et al. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology. 2004;208(1):43–8.PubMedGoogle Scholar
  77. 77.
    Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29(4):241–52.PubMedGoogle Scholar
  78. 78.
    Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer. 2000;88(1):88–94.PubMedGoogle Scholar
  79. 79.
    Balch CM, Soong SJ. Predicting outcomes in metastatic melanoma. J Clin Oncol. 2008;26(2):168–9.PubMedGoogle Scholar
  80. 80.
    Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15(5):1476–84.PubMedGoogle Scholar
  81. 81.
    Komorowski AL, Wysocki WM, White RL Jr. Surgical management of solitary metastatic melanoma. Acta Chir Belg. 2009;109(2):155–8.PubMedGoogle Scholar
  82. 82.
    Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7(11):919–24.PubMedGoogle Scholar
  83. 83.
    Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133(1):104–10.PubMedGoogle Scholar
  84. 84.
    Wasif N, Bagaria SP, Ray P, et al. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111–5.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Marchal F, Brunaud L, Bazin C, et al. Radiofrequency ablation in palliative supportive care: early clinical experience. Oncol Rep. 2006;15(2):495–9.PubMedGoogle Scholar
  86. 86.
    Marnitz S, Hoecht S, Hinkelbein W. The role of radiotherapy in the management of malignant melanoma. Front Radiat Ther Oncol. 2006;39:140–8.PubMedGoogle Scholar
  87. 87.
    Stevens G, McKay MJ. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol. 2006;7(7):575–83.PubMedGoogle Scholar
  88. 88.
    Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20 Suppl 6:vi22–9.Google Scholar
  89. 89.
    Geara FB, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am. 1996;76(6):1383–98.PubMedGoogle Scholar
  90. 90.
    Bhatnagar AK, Flickinger JC, Kondziolka D, et al. Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys. 2006;64(3):898–903.PubMedGoogle Scholar
  91. 91.
    Scorsetti M, Facoetti A, Navarria P, et al. Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases. Anticancer Res. 2009;29(10):4259–63.PubMedGoogle Scholar
  92. 92.
    Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, et al. Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. Actas Dermosifiliogr. 2009;100(7):571–85.PubMedGoogle Scholar
  93. 93.
    von Nida J, Quirk C. Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene. Australas J Dermatol. 2003;44(4):277–80.Google Scholar
  94. 94.
    Kandamany N, Mahaffey P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci. 2009;24(3):411–4.PubMedGoogle Scholar
  95. 95.
    Moreno-Ramirez D, de la Cruz L, Ferrandiz L, et al. Study and treatment of locally advanced melanoma. Actas Dermosifiliogr. 2009;100(9):767–79.PubMedGoogle Scholar
  96. 96.
    Moller MG, Salwa S, Soden DM, et al. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther. 2009;9(11):1611–30.PubMedGoogle Scholar
  97. 97.
    Snoj M, Cemazar M, Srnovrsnik T, et al. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori. 2009;95(3):398–402.PubMedGoogle Scholar
  98. 98.
    Deroose JP, Eggermont AM, van Geel AN, et al. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol. 2011;23(2):183–8.PubMedGoogle Scholar
  99. 99.
    Alexander HR Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol. 2010;28(1):114–8.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24(25):4196–201.PubMedGoogle Scholar
  101. 101.
    Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.PubMedGoogle Scholar
  102. 102.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Sznol M, Kluger H, Hodi F, et al. Survival and long-term follow-up of safety and response in patients with advanced melanoma in a phase I trial of nivolumab. J Clin Oncol. 2013;31 Suppl:abstr CRA9006.Google Scholar
  104. 104.
    Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.PubMedGoogle Scholar
  106. 106.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.PubMedGoogle Scholar
  109. 109.
    Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.PubMedGoogle Scholar
  110. 110.
    Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Ascierto P, Berking C, Agarwala S, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol. 2012;30 Suppl:abstr 8511.Google Scholar
  112. 112.
    Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001;11(1):75–81.PubMedGoogle Scholar
  113. 113.
    Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118–25.PubMedGoogle Scholar
  114. 114.
    Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–66.PubMedGoogle Scholar

Copyright information

© Springer Healthcare 2014

Authors and Affiliations

  • Alfonso Berrocal
    • 1
  • Luis Cabañas
    • 2
  • Enrique Espinosa
    • 3
  • Ricardo Fernández-de-Misa
    • 4
  • Salvador Martín-Algarra
    • 5
  • José Carlos Martínez-Cedres
    • 6
  • Luis Ríos-Buceta
    • 7
  • José Luis Rodríguez-Peralto
    • 8
  1. 1.Department of OncologyHospital General UniversitarioValenciaSpain
  2. 2.Department of SurgeryHospital Ramón y CajalMadridSpain
  3. 3.Department of Clinical OncologyHospital Universitario La PazMadridSpain
  4. 4.Department of DermatologyHospital Nuestra Señora de CandelariaSta. Cruz De TenerifeSpain
  5. 5.Department of OncologyClínica Universidad de NavarraPamplonaSpain
  6. 6.Department of Radiotherapeutic OncologyHospital Nuestra Señora de CandelariaSta. Cruz De TenerifeSpain
  7. 7.Department of DermatologyHospital Ramón y CajalMadridSpain
  8. 8.Department of PathologyHospital Universitario 12 de OctubreMadridSpain

Personalised recommendations